levodopa-carbidopa

ApprovedSmall molecule

levodopa-carbidopa is one of 104 small molecule programs targeting Anterior Ischemic Optic Neuropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

103

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anterior Ischemic Optic NeuropathyActive, not recruiting

StrokeActive, not recruiting

Retinitis PigmentosaActive, not recruiting

Parkinson DiseaseActive, not recruiting

Anterior Ischemic Optic NeuropathyApproved

Active, not recruiting

StrokeApproved

Active, not recruiting

Retinitis PigmentosaPhase 2

Active, not recruiting

Parkinson DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

levodopa-carbidopa

AbbVie

Approved

1 2

Zometa

Pfizer

Preclinical

1 3

Proamatine

Pradaxa

3 5

Botox

RRevance Therapeutics, Inc.

Preclinical

2 6

Direct Anticoagulant

Bayer

Preclinical

3 7

Inderal

Mylan Pharmaceuticals Inc

Anticoagulants

1 9

Anticoagulant

Bayer

Preclinical

1 10

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Parkinson Disease

NCT07246278

Phase 2/3Recruiting

Parkinson Disease

NCT06113640

Q3 2027

Phase 2/3Recruiting

Parkinson Disease

NCT07229651

Q4 2027

Phase 2/3Recruiting

Parkinson

NCT07229664

Clinical

Trials by Indication[1]

Parkinson's Disease6 trials

Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease

Completed·OOsmotica Pharmaceutical US LLC·Phase 2·NCT00558337·78 enrolled

Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease

Completed·TTanta University·Phase 2·NCT05781711·60 enrolled

Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Recruiting·TTanta University·Phase 2·NCT07001150·50 enrolled

Show 3 more trials

A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease

Completed· AbbVie logo

AbbVie·Phase 1·NCT01484990·19 enrolled

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT01736176·39 enrolled

Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease

Active, not recruiting·NNimble Science Ltd.··NCT06003608·100 enrolled

Parkinson disease3 trials

Celecoxib in Parkinson Disease as Adjuvant Therapy

Recruiting·TTanta University·Phase 1/2·NCT07246278·80 enrolled

Metformin in Parkinson Disease

Recruiting·TTanta University·Phase 2/3·NCT07229651·60 enrolled

Montelukast in Parkinson Disease

Recruiting·MMostafa Bahaa·Phase 2/3·NCT06113640·60 enrolled

Parkinson1 trial

Vinpocetine in Patients With Parkinsonian Disease

Recruiting·TTanta University·Phase 2/3·NCT07229664·60 enrolled

TED1 trial

Pharmacokinetic Study With Repeated Doses of Stalevo

Completed· Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma·Phase 1·NCT00693862·19 enrolled

Anterior Ischemic Optic Neuropathy1 trial

Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy

Completed·SShahid Beheshti University of Medical Sciences·Phase 4·NCT00432393

3 more indications

Stroke1 trial

Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation

Withdrawn·—·Phase 4·NCT02346630

Retinitis Pigmentosa1 trial

Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa

Unknown status·—·Phase 2·NCT02837640·50 enrolled

Neuromodulation1 trial

Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES

Completed·—·Phase 1·NCT04052776·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for levodopa-carbidopa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — levodopa-carbidopa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for levodopa-carbidopa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AbbVie

levodopa-carbidopa

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

Parkinson's Disease6 trials

Parkinson disease3 trials

Parkinson1 trial

TED1 trial

Anterior Ischemic Optic Neuropathy1 trial

Stroke1 trial

Retinitis Pigmentosa1 trial

Neuromodulation1 trial

References

Drug Info

Quick Facts

Related News